Anavex Life Sciences Corp (AVXL)

[falconer66a]

So what. How do they compare?

And there are S1 agonists under clinical trials for CNS diseases, as well as some already commercially available.

Do you mean to imply that not only are there other sigma-1 ligands, that might be "agonistic," but they have produced clinical data showing that they are better than the data from blarcamesine?

Again, I invite the posting of such data. Convince those of us who have actually scrutinized and understood the cellular chemistry of blarcamesine that blarcamesine won't cut it; won't be approved by the TGA or the FDA; and the any of the other sigma-1 ligand molecules will.

Most readers here strive to make the best equity investment decisions. Help us out. Show the data that show the other sigma-1 receptor molecules to be better than blarcamesine. I've got a lot of money tied up in my AVXL position, continually evaluating all appropriate data and info. Show me, with real, published numbers, that blarcamesine won't beat your "other S1 agonists."

The investment game is not won by merely noting there are many players. One needs to pick the winners of the tournament. The published data and information show that blarcamesine will do this. The "other S1 agonists" haven't scored. A few foul balls, but not a one has won a game against blarcamesine.